Erlotinib Terminated Phase 2 Trials for Bladder Carcinoma / Recurrent Bladder Carcinoma Treatment

IndicationsStatusPurposePhase
TerminatedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT02169284Erlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing Surgery